Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_18_suppst18.xlsx › Sheet1
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
33802174 (PubMed )
Supplement: cancers-13-01215-s001.zip › Supplymentary_files › Supplymental_table.xlsx › TableS1
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC et al.
Bmc Cancer, 2021
Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status.
Reder H et al.
Cancer Medicine, 2021
33527763 (PubMed )
Supplement: CAM4-10-1347-s006.pdf
Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma.
Hirotsu Y et al.
Scientific Reports, 2020
Patterns of genomic evolution in advanced melanoma.
Birkeland E et al.
Nature Communications, 2018
29991680 (PubMed )
Supplement: 41467_2018_5063_MOESM7_ESM.xlsx › mutationsInDriverGenes_withDriv
PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.
Li AJ et al.
World Journal of Gastroenterology, 2018
Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma.
Hirotsu Y et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology, 2016
26850916 (PubMed )
Supplement: supplement_1.xlsx › Table_S4
Select a paper to view details